BR112015022189A2 - microvesícula, método para produção e uso da mesma - Google Patents

microvesícula, método para produção e uso da mesma

Info

Publication number
BR112015022189A2
BR112015022189A2 BR112015022189A BR112015022189A BR112015022189A2 BR 112015022189 A2 BR112015022189 A2 BR 112015022189A2 BR 112015022189 A BR112015022189 A BR 112015022189A BR 112015022189 A BR112015022189 A BR 112015022189A BR 112015022189 A2 BR112015022189 A2 BR 112015022189A2
Authority
BR
Brazil
Prior art keywords
microvesicles
transgene
lentivirus
microvesicle
released
Prior art date
Application number
BR112015022189A
Other languages
English (en)
Inventor
Feng Luo
Katsura Misako
Li Zhong
Original Assignee
Katsura Misako
Li Zhong
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Katsura Misako, Li Zhong filed Critical Katsura Misako
Publication of BR112015022189A2 publication Critical patent/BR112015022189A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Urology & Nephrology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

resumo patente de invenção: "microvesícula e método para produção da mesma". a presente invenção refere-se a um método de fabricação para microvesículas contendo rna de lentivírus tendo um produto transgênico e/ou um transgene, o método incluindo uma etapa onde células são culturadas após terem um transgene introduzido nas mesmas usando um vetor de lentivírus a partir do qual pelo menos um gene de proteína estrutura foi deletado, e que contém um transgene sob o controle de um promotor do gene da transcriptase reversa da telomerase (tert) na sequência de genoma de lentivírus, e então microvesículas contendo o rna de lentivírus tendo um produto de transgene e/ou transgene são liberadas para o exterior da célula e uma etapa onde as microvesículas liberadas são coletadas; as microvesículas obtidas usando o dito método; e usos para as ditas microvesículas.
BR112015022189A 2013-03-13 2014-03-13 microvesícula, método para produção e uso da mesma BR112015022189A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361779556P 2013-03-13 2013-03-13
US201361894563P 2013-10-23 2013-10-23
PCT/JP2014/056651 WO2014142235A1 (ja) 2013-03-13 2014-03-13 微小胞及びその製造方法

Publications (1)

Publication Number Publication Date
BR112015022189A2 true BR112015022189A2 (pt) 2017-11-21

Family

ID=51536884

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015022189A BR112015022189A2 (pt) 2013-03-13 2014-03-13 microvesícula, método para produção e uso da mesma

Country Status (12)

Country Link
US (2) US20160060652A1 (pt)
EP (1) EP2975125B1 (pt)
JP (1) JP6250631B2 (pt)
KR (1) KR102156290B1 (pt)
CN (1) CN105209617B (pt)
AU (1) AU2014230599B2 (pt)
BR (1) BR112015022189A2 (pt)
CA (1) CA2904802C (pt)
MY (1) MY177482A (pt)
RU (1) RU2693088C2 (pt)
TW (1) TWI582232B (pt)
WO (1) WO2014142235A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015019505A1 (ja) * 2013-08-09 2015-02-12 永田 啓司 レンチウイルスベクターthtd、該thtdを含有する老化材
CA3032412A1 (en) * 2016-07-29 2018-02-01 Ohio State Innovation Foundation Expression of pten-long with ocolytic viruses
JP2018070572A (ja) * 2016-10-24 2018-05-10 義之 小山 免疫治療システム
CN108066361A (zh) * 2017-01-23 2018-05-25 广州中科蓝华生物科技有限公司 一种外泌体，其制备方法及其在制备抗肿瘤的药物或者制剂中的用途
CN109528653B (zh) * 2018-11-22 2020-07-31 北京大学 具有基因编辑功能的膜性囊泡及其制备方法、药物组合物和用途
US20220409741A1 (en) * 2019-09-02 2022-12-29 Kyungpook National University Industry-Academic Cooperation Foundation Composition for preventing or treating cancer, containing il-2 surface expression-extracellular vesicles as active ingredient
WO2022139530A1 (ko) * 2020-12-23 2022-06-30 주식회사 리스큐어바이오사이언시스 락토바실러스 사케아이 유래 세포밖 소포체를 유효성분으로 포함하는 자가면역질환의 개선, 예방 또는 치료용 조성물
CN118006550A (zh) * 2024-04-07 2024-05-10 四川天府亨特生命科技有限公司 一种细胞培养基提取外泌体的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ137399A3 (cs) * 1996-10-17 1999-07-14 Oxford Biomedica (Uk) Limited Retrovirový produkční systém pro produkci replikačně defektivních vektorovýh partikulí
GB9621680D0 (en) * 1996-10-17 1996-12-11 Oxford Biomedica Ltd Lentiviral vectors
US7598077B2 (en) * 2003-06-05 2009-10-06 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for enhancing differential expression
SG10201502098YA (en) * 2006-10-17 2015-05-28 Oncotherapy Science Inc Peptide Vaccines For Cancers Expressing MPHOSPH1 OR DEPDC1 Polypeptides
EP2604271B1 (en) 2007-10-29 2014-09-17 Fresenius Medical Care Deutschland GmbH A stem cell-derived microvesicle (MV) for use in inhibiting apoptosis induced by a cytostatic agent
EP2448595B1 (en) 2009-07-02 2017-06-14 ITH Immune Therapy Holdings AB Exosome based treatment of cancer
JP2013510563A (ja) * 2009-11-13 2013-03-28 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 操作された微小胞を用いた真核細胞のリプログラミング
ES2362589B1 (es) 2009-12-28 2012-05-16 Centre De Recerca En Salut Internacional De Barcelona Exosomas derivados de reticulocitos infectados con plasmodium sp., método para su obtención y su uso.
WO2011106376A2 (en) * 2010-02-23 2011-09-01 The General Hospital Corporation Use of microvesicles in the treatment of medical conditions
CN101869715A (zh) * 2010-05-26 2010-10-27 江苏命码生物科技有限公司 载有干扰核糖核酸的细胞微粒子、其制备方法及其应用
US9816998B2 (en) * 2011-04-01 2017-11-14 Cornell University Circulating exosomes as diagnostic/prognostic indicators and therapeutic targets of melanoma and other cancers
WO2013109713A1 (en) * 2012-01-18 2013-07-25 The General Hospital Corporation Targeting rnas to microvesicles

Also Published As

Publication number Publication date
JPWO2014142235A1 (ja) 2017-02-16
CA2904802C (en) 2021-03-30
KR20150133753A (ko) 2015-11-30
TW201443233A (zh) 2014-11-16
EP2975125A1 (en) 2016-01-20
RU2015143513A (ru) 2017-04-20
US20160060652A1 (en) 2016-03-03
RU2693088C2 (ru) 2019-07-01
KR102156290B1 (ko) 2020-09-15
EP2975125A4 (en) 2016-10-26
TWI582232B (zh) 2017-05-11
CN105209617A (zh) 2015-12-30
AU2014230599B2 (en) 2020-02-27
EP2975125B1 (en) 2020-04-29
CN105209617B (zh) 2018-10-16
WO2014142235A1 (ja) 2014-09-18
AU2014230599A1 (en) 2015-10-29
JP6250631B2 (ja) 2017-12-20
CA2904802A1 (en) 2014-09-18
MY177482A (en) 2020-09-16
US20200407752A1 (en) 2020-12-31

Similar Documents

Publication Publication Date Title
BR112015022189A2 (pt) microvesícula, método para produção e uso da mesma
EA201492202A1 (ru) Способ экспрессии гетерологичных белков с использованием рекомбинантного вирусного вектора с минус-нитью рнк
AR115692A2 (es) Método para la producción de promotores constitutivos de plantas, constructos y células transgénicas
MX2018011384A (es) Arn de replicacion en trans.
BR112018004725A2 (pt) método para a produção de oligossacarídeos de leite humano em hospedeiros microbianos com importação/exportação modificada e célula hospedeira microbiana
BR112018007070A2 (pt) método, composição e kit para a preparação de uma planta a partir de um protoplasto, planta regenerada e composição para clivagem de dna
BR112017007770A2 (pt) cultura in vitro, população de hipscs, método para modificar um locus-alvo genômico, e, hipsc.
BR112016015187A2 (pt) proteína de fusão para inibição da angiogênese ou do crescimento e uso da mesma
WO2008145400A3 (en) Mutated structural protein of a parvovirus
BR112015030491A8 (pt) método de modular a expressão de um ácido nucleico alvo em uma célula, bem como método de alterar um ácido nucleico de dna alvo em uma célula
BR112018010429A2 (pt) ácidos nucleicos que se direcionam a ácidos nucleicos engenheirados
BRPI0924899B8 (pt) Síntese hmo
CO7170149A2 (es) Producción mejorada de derivados de ácidos grasos
BR112018012887A2 (pt) molécula de ácido nucleico, cassete de expressão, vetor, célula vegetal, planta, método para expressar um polinucleotídeo
BR112017027527A2 (pt) ?método para a produção de feromônios de mariposas em levedura
BRPI0821034A8 (pt) Vírus influenza b recombinante, seu uso, metodo de preparação, composição de vacina o contendo e seu gene m, bem como ácido nucléico isolado, molécula do vírus influenza m e seu uso e método para aumentar a taxa de crescimento de vírus influenza b deficiente de replicação
BR112022011904A2 (pt) Produção de oligossacarídeo sialilado em células hospedeiras
BR112014026053A2 (pt) método de preparo de para-xileno a partir de biomassa
BR112015005604A2 (pt) vetores de expressão compreendendo sequências de potencializador e promotor de citomegalovírus quimérico
BR112017018704A2 (pt) métodos para produção de células troncos neurais e usos das mesmas
BR112022009836A2 (pt) Método para fornecer células imunes com função aumentada
BR112018071376A2 (pt) método para modificar um sítio alvejado de um dna de cadeia dupla, complexo enzimático modificador de ácido nucleico, e, ácido nucleico
BR112015022495A8 (pt) Cassete de expressão e método para expressar uma sequência nucleotídica em uma célula vegetal
AR092630A1 (es) Metodos y composiciones para prevenir la incorporacion erronea de norleucina en proteinas
BR112016014646A2 (pt) Planta transformada e método para a produção de exsudato contendo açúcar com o uso de planta transformada

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.